The EU Health Technology Assessment Regulation (HTAR), effective from January 12, 2025, aims to harmonize the evaluation of health technologies across member states to enhance patient access to innovative treatments.
In this latest article from Pamela Vo, PharmD, MS, VP, HEOR, Value & Evidence and Ray Gani, PhD, VP HEOR Market Access, Value & Evidence – Europe, learn more about this regulation and the introduction of a Joint Clinical Assessment (JCA) process, enabling timely and informed decisions regarding the pricing and reimbursement of health products.
Download the full article to gain deeper insights into the new regulation and the impact on the EU market.
Author
Pamela Vo brings over 18 years of HEOR experience in the pharmaceutical industry, showcasing a history of strategically translating ideas into impactful outcomes. She boasts a proven track record of peer-reviewed publications, significant achievements…